<DOC>
	<DOCNO>NCT00176423</DOCNO>
	<brief_summary>The purpose study examine whether adjunctive galantamine effective treatment cognitive impairment patient schizophrenia .</brief_summary>
	<brief_title>Efficacy Study Galantamine Cognitive Impairments Schizophrenia</brief_title>
	<detailed_description>Patients schizophrenia characterize broad range neurocognitive abnormality . These include impairment attention ; eye-tracking ; visual verbal memory ; work memory ; process speed ; sensory gating , measure P50 . These impairment major determinant poor functional outcome patient schizophrenia . Conventional antipsychotic limited effect impairment . Second generation antipsychotic ( SGAs ) may modest benefit cognitive function , whether represent direct cognitive enhance effect establish . Regardless , patient continue exhibit pronounced cognitive impairment despite adequate new generation antipsychotic treatment . Adjunctive pharmacotherapy may offer viable approach treatment cognitive impairment . Adjunctive agent use modulate specific neurotransmitter system hypothesize involved pharmacology cognitive function . Acetylcholine act muscarinic nicotinic cholinergic receptor . These receptor broadly distribute brain , include neocortex , hippocampus , basal ganglion . Cholinergic mechanisms implicate regulation attention , memory , process speed , sensory gating process ; process impair patient schizophrenia . Nicotine previously show improve sensory gating , measure P50 , eye-tracking patient schizophrenia . The gene alpha-7 nicotinic receptor , hypothesize nicotinic receptor involve sensory gate regulation , also show link schizophrenia . Galantamine ( Trade name : Reminyl ) new FDA-approved selective acetylcholinesterase inhibitor ( AChEI ) , may also allosterically modulate nicotinic receptor , enhance receptor sensitivity , increase nicotinic receptor density . Galantamine market Janssen Research Foundation . In animal model age , galantamine enhance long-term potentiation , ameliorate learning impairment , elevate number nicotinic receptor hippocampus neocortex . In placebo-controlled study , galantamine show delay deterioration improve cognitive function patient Alzheimer â€™ disease . There also preliminary evidence galantamine may ameliorate positive psychotic symptom patient . AChEIs extensively study patient schizophrenia . We conduct 6-week open-labeled pilot study adjunctive donepezil patient treat olanzapine minimum 6 month . Fifteen patient enter study 14 patient complete study . One patient withdraw complaint sedation . The demographic characteristic patient complete study : mean ( SD ) age : 43.1 6.6 ; 71 % male ; 78 % caucasian ; mean ( SD ) duration illness : 24.7 7.2 . The mean ( SD ) olanzapine dose 25.7 11.9 mg/day . Two patient receive benzodiazepine , two receiving antidepressant , one receiving valproic acid . Donepezil result modest improvement sensory gating . Nine patient abnormal P50 baseline , normalized five patient follow treatment . Donepezil pronounce effect neuropsychological test performance , large significant effect size observe visual memory ( effect size ( ES ) =.57 ) manual dexterity ( ES=.93 ) measure . There moderate improvement verbal recall memory ( ES=0.46 ) process speed ( ES=0.48 ) measure . The cognitive measure change treatment measure attention . There significant change either positive symptom ( mean ( SD ) , baseline : 9.3 3.8 ; week 6 : 8.2 3.8 ; t=-1.55 , df=14 , p=.14 ) negative symptom ( mean ( SD ) , baseline : 29.7 10.9 ; week 6 : 30.0 12.6 ; t=0.15 , df=14 , p=.88 ) measure . The result study suggest adjunctive AChEIs may effective treatment cognitive impairment patient schizophrenia . Moderate large effect size improvement observe verbal visual memory , process speed , manual dexterity measure . Patients exhibit great 20 % increase suppression P50 response repeat auditory stimulus . There effect donepezil measure attention . Donepezil well tolerate ; one patient drop study nine remain subject chose continue drug beyond protocol . An important aspect study cognitive function improvement occur context concurrent olanzapine treatment , report improve P50 cognitive function ( Purdon et al , 2000 ; Light et al , 2000 ) . Thus , donepezil able enhance cognitive function patient may already benefit olanzapine treatment . The primary study objective : 1 . To examine whether adjunctive galantamine effective placebo neuropsychological measure attention , verbal visual memory , work memory , process speed , manual dexterity . 2 . To examine whether adjunctive galantamine effective placebo evoke potential measure sensory gating ( i.e. , P50 ) attention ( i.e. , P300 Gamma Band Response ( GBR ) ) smooth pursuit eye movement . We hypothesize galantamine significant benefit cognitive behavior base role acetylcholine regulation behavior ; pilot study donepezil demonstrate AChEIs may beneficial effect verbal visual memory , process speed , manual dexterity ; previous study show acute nicotine administration normalize P50 eye-tracking patient schizophrenia . The secondary study objective : 1 . To examine whether adjunctive galantamine effective placebo positive symptom negative symptom measure . 2 . To examine whether adjunctive galantamine likely placebo cause nausea , vomit , diarrhea , anorexia , weight loss , dizziness , i.e. , common side effect associate AChEI treatment . 3 . To examine whether galantamine likely placebo cause increase either extrapyramidal symptom dyskinetic movement . 4 . To examine whether galantamine effective placebo reduce smoke behavior . We hypothesize significant difference galantamine placebo positive negative symptom base donepezil pilot study . We hypothesize galantamine associate increased incidence AChEI associate side effect . We hypothesize significant difference galantamine placebo either extrapyramidal symptom dyskinetic movement . Study Design Methods : The propose study randomize , parallel group , double-blind comparison adjunctive galantamine placebo . The sample consist 90 clinically stable inpatient outpatients DSM-IV schizophrenia schizoaffective disorder . There 2-week stabilization phase , 12-week treatment phase , optional 6-month open-label phase . In 2-week stabilization phase , patient undergo baseline symptom , medical , safety , antipsychotic level , neurocognitive assessment . In 12-week treatment phase , patient randomize either galantamine placebo . Patients receive biweekly symptom , side effect , vital sign assessment . At end study ( 12 week ) , laboratory test , EKG , antipsychotic level , neurocognitive assessment repeat . Patients monitor 3-month 6-month point open-labeled phase , receive laboratory test , EKG , side effect review . At end 6-month open-labeled phase , patient ask participate symptom rating neuropsychological test .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>1 . DSMIV diagnosis either schizophrenia schizoaffective disorder . 2 . Males females 3 . Age : 18 60 4 . Caucasian NonCaucasian 5 . Subjects currently treat one follow new generation antipsychotic : olanzapine , risperidone , quetiapine , ziprasidone , aripiprazole . 6 . Subjects meet priori criterion cognitive impairment severity . The Repeatable Battery Assessment Neuropsychological Status ( RBANS ) use determine level cognitive impairment . Patients meet entry criterion RBANS total score 90 less ( one standard deviation normal control mean ) . 1 . History organic brain disease 2 . History DSMIV alcohol substance abuse ( within last month ) , DSMIV alcohol substance dependence ( within last six month ) . 3 . Pregnant woman woman take oral contraceptive ( theoretical risk breakthrough ovulation ) . 4 . Current treatment galantamine acetylcholinesterase inhibitor ( e.g . donepezil ) 5 . History second third degree atrioventricular ( AV ) block . 6 . Persons chronic medical condition , unstable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>acetylcholine</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>attention</keyword>
	<keyword>process speed</keyword>
	<keyword>sensory gating</keyword>
	<keyword>eye-tracking</keyword>
</DOC>